Nature’s Sunshine spent most of its life as a quiet Utah supplement maker, selling herbal capsules through a network of independent distributors rather than retail shelves. The pandemic gave it a brief, dazzling moment: revenue jumped sharply in 2021 as consumers stocked up on immunity products. Then the moment passed. Sales slid, earnings swung to a small loss in 2022, and the stock spent the next few years searching for a reason to matter. What’s odd is what happened next: the fundamentals quietly improved, and the stock fell anyway.
Six months ago the shares traded near $28. Today they sit at $12.64, more than half the value gone, even as the company’s own filings show margins expanding and the balance sheet carrying no debt at all. That gap between what the business is doing and what the market is paying for it is the whole story here.
The heart of it
The filed numbers show a business earning more on each dollar of sales than it has in years, with cash in the bank and nothing owed to lenders. The stock is priced near its cheapest level in a decade relative to earnings, our data show. Those two readings cannot both be right, and the open question is whether the market sees a deterioration the filings have not yet revealed, or whether the price has simply run ahead of the fear.
What the filings actually show
The 10-K for fiscal year 2025 is the place to start. Revenue reached $480 million, up about 6% from the prior year, and net margin more than doubled compared to what the 2024 annual filing reported. That margin recovery is not a rounding error. On nearly half a billion dollars of sales, the difference adds roughly $11 million of additional profit reaching the bottom line. For a company this size, that is a meaningful shift.
The most recent quarterly picture, from the 10-Q for the quarter ended June 30, 2026, filed August 6, extends the trend. Gross profit margin, the share of each sales dollar left after making and delivering the product, reached a historically high level in the second quarter. Operating income, what remains after running the business day to day, rose sharply year over year even as sales grew only modestly. A business that earns more without selling more is doing something right internally.
The balance sheet deserves its own sentence. As of June 30, 2026, the company held $82.5 million in cash and carried no debt. That cash pile equals roughly two full years of the operating income the business is currently generating. A company with no debt and two years of earnings sitting in the bank has options: it can buy back shares, acquire a competitor, or simply wait out a rough patch without anyone calling a loan.
Where the math and the mood diverge
“The math” is what the filed fundamentals describe: a business earning more, carrying no debt, and guiding toward roughly half a billion dollars in sales for the full year. “The mood” is what the market is currently paying: a price-to-earnings multiple of 11.5 times, against a decade median of 21.6 times for this same company, our data show. Sitting at the first percentile of its own valuation history means the stock has almost never been cheaper relative to its earnings, at least not in the past ten years.
The mood is not irrational on its face. Nature’s Sunshine sells through independent distributors, a channel that has struggled across the direct-sales industry as social media upended traditional word-of-mouth recruiting. The 2023 10-K flagged distributor recruitment and retention as a persistent risk, and nothing in the more recent filings suggests that structural challenge has been solved. Currency is another drag: the company operates across dozens of countries, and a strong dollar quietly shrinks the value of overseas sales when converted back to U.S. figures. The 10-Q for the quarter ended June 30, 2026 notes that constant-currency growth ran meaningfully ahead of reported growth, meaning a significant slice of headline progress was absorbed by exchange rates before it reached the income statement.
So the mood has a case. The math also has a case. They are not yet reconciled.
Reading the numbers
- $480M in FY2025 revenue, up 5.7%. From the 2025 10-K. Growing at roughly the pace of the broader economy. Not exciting, but stable. For a business that lost ground in 2022, stability is progress.
- Net margin of 4.1% in FY2025 vs. 1.7% in FY2024. Think of it this way: on every $100 of sales, the company kept $4.10 last year versus $1.70 the year before. That extra $2.40 per $100 compounds across nearly half a billion dollars of revenue.
- 73.7% gross margin in Q2 2026. From the Q2 2026 10-Q. For every dollar a customer spends on a Nature’s Sunshine product, about 74 cents remains after the cost of making it. That is a high ratio, typical of branded supplement businesses where the formula and the label carry more value than the raw ingredients.
- $82.5M cash, zero debt, as of June 30, 2026. A household analogy: imagine owning a home outright and having two years of salary in savings. The business has no lender who can force its hand.
- P/E of 11.5 vs. decade median of 21.6. Our data. IF the multiple were to revert to its own decade median of 21.6 times and IF earnings held near their current filed level, the same arithmetic would point to a price roughly in the range of $24 to $28, but the data cannot tell us whether the depressed multiple reflects a risk the filings have not yet disclosed, and no reversion is assumed or implied.
Sources
- NATR 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Nature’s Sunshine Q2 2026 press release (IR site)
- NATR 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- NATR 10-K, fiscal year ended December 31, 2024 (SEC EDGAR)
- NATR 10-K, fiscal year ended December 31, 2023 (SEC EDGAR)
